Tag
The LATA trial demonstrates that long-acting injectable cabotegravir-rilpivirine given every 8 weeks is superior to daily oral ART for maintaining virological suppression in adolescents with HIV in sub-Saharan Africa, with a favorable safet
Removal of Medicaid prescription caps in South Carolina improved antiretroviral therapy adherence and HIV medication fills among people with HIV, though no significant health care utilization changes were noted, suggesting need for compleme
This study explores how various social adversity domains affect mortality and rehospitalization risks in HIV-positive patients with heart failure, underscoring the importance of holistic social assessments for improving outcomes.
The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w
Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditi
This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living wi
A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, high
A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and
This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention a
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation
First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr
In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage com
Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction
Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.
Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.
Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
This review synthesizes motivations, facilitators, and barriers of donation-based interventions in HIV/STI research, revealing key factors that enhance access to services through prosocial behaviors in diverse global settings.
This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV r
Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.
